MacularorRetinalEdema near Teaneck, NJ

Biography: Brian Marr, MD heads the Ophthalmic Oncology Service at the Harkness Eye Institute. He has comprehensive experience in the diagnosis, treatment, and management of ocular tumors including intraocular tumor resection, laser, radiation, and chemotherapy procedures. He has helped devise thousands of complex treatments for tumors of the eye, eyelid, orbit, and conjunctiva for his adult, children, and infant patients. Currently, Dr. Marr is a collaborator on a Columbia University clinical trial for a first-of-its-kind, new class of drug treatment for uveal melanoma. Dr. Marr is a board-certified ophthalmologist whose work has centered around ophthalmic oncology since 2000. One of the very few ocular oncologists trained in all aspects of eye cancer, Dr. Marr's clinical experience in treating these diseases is among the most extensive in the United States. His interest and experience in ophthalmic oncology began during an eight-year tenure in the Ocular Oncology Service at the Wills Eye Hospital in Philadelphia. There, he gained extensive experience treating intraocular tumors, and tumors of the eyelid, orbit, and conjunctiva in children and adults. It was there that Dr. Marr developed and improved many surgical procedures used to cure cancers of the eye, successfully treated thousands of patients, and helped their families though their battle with eye cancer. Next, Dr. Marr moved on to Memorial Sloan Kettering Cancer Center, where he remain for nine years, starting in 2008. Dr. Marr has some of the greatest experience with intra-arterial chemotherapy for treating retinoblastoma in the country, if not the world, as well as all other forms of retinoblastoma treatment. He has been a key member of many multidisciplinary surgical teams, treating advanced skull base tumors and complex facial skin lesions. He has developed a strong belief and treatment philosophy that the best research be used to help his patients, rather than his best patients be used to help his research. The field of ophthalmic oncology encompasses many rare conditions and his experience helps his patients get the best care and results as quickly as possible. Dr. Marr lectures and consults across the US and abroad, and has authored numerous research articles in the field of ocular oncology. He is the principal investigator in a first-in-class drug study for treating primary uveal melanoma, in an international, multi-center trial. He also volunteers his medical expertise in underserviced parts of the world, such as Nigeria and Indonesia, and has helped train physicians in more than 20 countries. Dr. Marr's efforts as a contributor to ongoing education in ocular oncology have been recognized by the American Academy of Ophthalmology, where he now serves as chief editor of the Academy's Oncology and Pathology's One network.

Care Philosophy: As a caring and dedicated physician, my mission is to provide excellent care to my patients. With my dual training in both Ophthalmology and Neurology, I am well suited to take care of patients with visual dysfunction caused by diseases of the eye and brain.

Biography: After graduating magna cum laude from Rensselaer Polytechnic Institute with a Bachelor of Science in biochemistry/biophysics, Dr. Haqqie graduated from Albany Medical College cum laude. She was inducted into the Alpha Omega Alphahonor society her junior year of medical college. She completed her residencyat Albany Medical College where she was selected to serve as chief resident in her final year and was awarded the Robert Reinecke research award. Dr. Haqqie then went on to complete her fellowship in cornea, cataract, and refractive surgery at Weill Cornell Medical College in New York, New York.Dr. Haqqie was previously the assistant director of the Wills Eye Hospital Emergency Department. During her time at Wills Eye Hospital, she was the recipient of the Residency Advocacy Award in 2021 and 2023. She also received the Exemplary Teacher Award from the national organization, Real World Ophthalmology. Dr. Haqqie has been recognized as a gifted educator and has astrong interest in teaching the next generation of ophthalmologists.Dr. Haqqie is author and co-author of numerous journal articles and national presentations. Her areas of clinical and research interest include ocularsurface disease, cataract surgery, and ocular emergencies.Dr. Haqqie is a diplomat of the American Board of Ophthalmology and a member of the American Academy of Ophthalmology, American Society of Cataract & Refractive Surgeons, and is an active member of various professional societies. She is committed to excellence in the provision of a complete range of ophthalmic service. Her practice interests include comprehensive ophthalmology, advanced corneal, cataract, and laser vision correction. Dr. Haqqie is currently accepting new patients; appointments can be made by calling 646-962-2020.

Biography: Scott E. Brodie, MD, Ph.D., is a Professor of Clinical Ophthalmology and Attending Ophthalmologist in the Department of Ophthalmology. He is an internationally known clinician-scientist, and a leader in the use of electrophysiologic techniques for diagnosing of visual impairments in children and adults. Dr. Brodie is a graduate of the combined MD-PhD program at Weill-Cornell Medical College and The Rockefeller University in New York. He completed his PhD in retinal physiology in the laboratory of Nobel Laureate H. K. Hartline, under the supervision of Dr. Floyd Ratliff and Prof. Bruce Knight. He completed a medical internship and residency training in ophthalmology at The New York Hospital, and subsequently received fellowship training in medical retinal disorders and clinical electrophysiology of vision at New York University and Bellevue Hospital under the supervision of Dr. Ronald Carr, with support as a John Kluge Fellow of the Retinitis Pigmentosa Foundation. He is a fellow of the American Academy of Ophthalmology, and a member of the Association for Research in Vision and Ophthalmology, the International Society for Clinical Electrophysiology of Vision, the International Society for Genetic Eye Disease, and the Ophthalmic Genetics Study Club. He is a Fellow of the Association for Research in Vision and Ophthalmology, and has been honored with the Senior Achievement Award of the American Academy of Ophthalmology, as well as the Academy's Secretariat Award for Education. Dr. Brodie's research centers on improving methodologies for electrophysiologic testing, and descriptions of novel findings in patients with inherited and metabolic retinal disorders. He has been a key member of the teams which have introduced important new therapies, including enzyme-replacement therapy for Fabry disease, and intra-arterial chemotherapy for retinoblastoma, which has increased the rate of salvage of diseased eyes in the most severely affected patients from 20% to 80%. Dr. Brodie has published extensively on electrophysiology and retinal disorders. He has a particular interest in clinical optics, and has served as Chair of the Editorial committee for the American Academy of Ophthalmology's Basic and Clinical Science Course on Clinical Optics for the past eight years. In his spare time, he enjoys reading mathematics, and playing the oboe in local orchestras and chamber groups.